Stephen J. Halliday
Vanderbilt University Medical Center
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Stephen J. Halliday.
Pulmonary circulation | 2016
Tufik R. Assad; Evan L. Brittain; Quinn S. Wells; Eric Farber-Eger; Stephen J. Halliday; Laura N. Doss; Meng Xu; Li Wang; Frank E. Harrell; Chang Yu; Ivan M. Robbins; John H. Newman; Anna R. Hemnes
Although commonly encountered, patients with combined postcapillary and precapillary pulmonary hypertension (Cpc-PH) have poorly understood pulmonary vascular properties. The product of pulmonary vascular resistance and compliance, resistance-compliance (RC) time, is a measure of pulmonary vascular physiology. While RC time is lower in postcapillary PH than in precapillary PH, the RC time in Cpc-PH and the effect of pulmonary wedge pressure (PWP) on RC time are unknown. We tested the hypothesis that Cpc-PH has an RC time that resembles that in pulmonary arterial hypertension (PAH) more than that in isolated postcapillary PH (Ipc-PH). We analyzed the hemodynamics of 282 consecutive patients with PH referred for right heart catheterization (RHC) with a fluid challenge from 2004 to 2013 (cohort A) and 4,382 patients who underwent RHC between 1998 and 2014 for validation (cohort B). Baseline RC time in Cpc-PH was higher than that in Ipc-PH and lower than that in PAH in both cohorts (P < 0.001). In cohort A, RC time decreased after fluid challenge in patients with Ipc-PH but not in those with PAH or Cpc-PH (P < 0.001). In cohort B, the inverse relationship of pulmonary vascular compliance and resistance, as well as that of RC time and PWP, in Cpc-PH was similar to that in PAH and distinct from that in Ipc-PH. Our findings demonstrate that patients with Cpc-PH have pulmonary vascular physiology that resembles that of patients with PAH more than that of Ipc-PH patients. Further study is warranted to identify determinants of vascular remodeling and assess therapeutic response in this subset of PH.
Chest | 2017
Matthew W. Semler; David R. Janz; Derek W. Russell; Jonathan D. Casey; Robert J. Lentz; Aline Zouk; Bennett P. deBoisblanc; Jairo I. Santanilla; Yasin A. Khan; Aaron M. Joffe; William S. Stigler; Todd W. Rice; Grady P. Creek; Jody L. Haddock; Derek J. Vonderhaar; Nicole C. Lapinel; Sneha D. Samant; Rose Paccione; Kevin Dischert; Abdulla Majid-Moosa; Joaquin Crespo; Michael B. Fashho; Daniel T. Matthews; Jeannette Zinggeler Berg; Tufik R. Assad; Andrew C. McKown; Luis E. Huerta; Emily G. Kocurek; Stephen J. Halliday; Vern E. Kerchberger
BACKGROUND: Hypoxemia is the most common complication during endotracheal intubation of critically ill adults. Intubation in the ramped position has been hypothesized to prevent hypoxemia by increasing functional residual capacity and decreasing the duration of intubation, but has never been studied outside of the operating room. METHODS: Multicenter, randomized trial comparing the ramped position (head of the bed elevated to 25°) with the sniffing position (torso supine, neck flexed, and head extended) among 260 adults undergoing endotracheal intubation by pulmonary and critical care medicine fellows in four ICUs between July 22, 2015, and July 19, 2016. The primary outcome was lowest arterial oxygen saturation between induction and 2 minutes after intubation. Secondary outcomes included Cormack‐Lehane grade of glottic view, difficulty of intubation, and number of laryngoscopy attempts. RESULTS: The median lowest arterial oxygen saturation was 93% (interquartile range [IQR], 84%‐99%) with the ramped position vs 92% (IQR, 79%‐98%) with the sniffing position (P = .27). The ramped position appeared to increase the incidence of grade III or IV view (25.4% vs 11.5%, P = .01), increase the incidence of difficult intubation (12.3% vs 4.6%, P = .04), and decrease the rate of intubation on the first attempt (76.2% vs 85.4%, P = .02), respectively. CONCLUSIONS: In this multicenter trial, the ramped position did not improve oxygenation during endotracheal intubation of critically ill adults compared with the sniffing position. The ramped position may worsen glottic view and increase the number of laryngoscopy attempts required for successful intubation. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT02497729; URL: www.clinicaltrials.gov
Chest | 2017
David R. Janz; Matthew W. Semler; Aaron M. Joffe; Jonathan D. Casey; Robert J. Lentz; Bennett P. deBoisblanc; Yasin A. Khan; Jairo I. Santanilla; Itay Bentov; Todd W. Rice; Grady P. Creek; Jody L. Haddock; Derek J. Vonderhaar; Nicole C. Lapinel; Sneha D. Samant; Rose Paccione; Kevin Dischert; Abdulla Majid-Moosa; Joaquin Crespo; Michael B. Fashho; Daniel T. Matthews; Jeannette Zinggeler Berg; Tufik R. Assad; Andrew C. McKown; Luis E. Huerta; Emily G. Kocurek; Stephen J. Halliday; Vern E. Kerchberger; Christopher Merrick; Melissa A. Warren
BACKGROUND: Hypoxemia and hypotension are common complications during endotracheal intubation of critically ill adults. Verbal performance of a written, preintubation checklist may prevent these complications. We compared a written, verbally performed, preintubation checklist with usual care regarding lowest arterial oxygen saturation or lowest systolic BP experienced by critically ill adults undergoing endotracheal intubation. METHODS: A multicenter trial in which 262 adults undergoing endotracheal intubation were randomized to a written, verbally performed, preintubation checklist (checklist) or no preintubation checklist (usual care). The coprimary outcomes were lowest arterial oxygen saturation and lowest systolic BP between the time of procedural medication administration and 2 min after endotracheal intubation. RESULTS: The median lowest arterial oxygen saturation was 92% (interquartile range [IQR], 79‐98) in the checklist group vs 93% (IQR, 84‐100) with usual care (P = .34). The median lowest systolic BP was 112 mm Hg (IQR, 94‐133) in the checklist group vs 108 mm Hg (IQR, 90‐132) in the usual care group (P = .61). There was no difference between the checklist and usual care in procedure duration (120 vs 118 s; P = .49), number of laryngoscopy attempts (one vs one attempt; P = .42), or severe life‐threatening procedural complications (40.8% vs 32.6%; P = .20). CONCLUSIONS: The verbal performance of a written, preprocedure checklist does not increase the lowest arterial oxygen saturation or lowest systolic BP during endotracheal intubation of critically ill adults compared with usual care. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT02497729; URL: www.clinicaltrials.gov.
Pulmonary circulation | 2017
Stephen J. Halliday; Anna R. Hemnes
Pharmacotherapeutic options for pulmonary arterial hypertension (PAH) have increased dramatically in the last two decades and along with this have been substantial improvements in survival. Despite these advances, however, PAH remains a progressive and ultimately fatal disease for most patients and only epoprostenol has been shown to improve survival in a randomized control trial. Clinical observations of the heterogeneity of treatment response to different classes of medications across the phenotypically diverse PAH population has led to the identification of patients who derive significantly more benefit from certain medications than the population mean, the so-called “super responders.” This was first recognized among PAH patients with acute vasodilator response during invasive hemodynamic testing, a subset of whom have dramatically improved survival when treated with calcium channel blocker (CCB) therapy. Retrospective studies have now suggested a sex discrepancy in response to endothelin receptor antagonists (ERA) and phosphodiesterase inhibitors, and more recently a few studies have found genomic associations with response to CCBs and ERAs. With increasing availability of “omics” technologies, recognition of these “super responders,” combined with careful clinical and molecular phenotyping, will lead to advances in pharmacogenomics, precision medicine, and continued improvements in survival among PAH patients.
Pulmonary circulation | 2018
Stephen J. Halliday; Meng Xu; Timothy Thayer; Jonathan D. Mosley; Quanhu Sheng; Fei Ye; Eric Farber-Eger; Meredith E. Pugh; Ivan R. Robbins; Tufik R. Assad; James West; Evan L. Brittain; Anna R. Hemnes
Parenteral prostacyclin therapy is the most efficacious pharmacologic treatment for pulmonary arterial hypertension (PAH), but clinical response is variable. We sought to identify clinical, hemodynamic, and genetic associations with response to prostacyclin therapy. We performed a retrospective analysis of patients within a de-identified electronic health record and associated DNA biobank. Patients with PAH and a right heart catheterization (RHC) in the six months before initiation of a parenteral prostacyclin were included. Responders were defined a priori by attainment of World Health Organization (WHO) functional class (FC) 2 or better at the time of repeat RHC within two years. We performed exploratory analyses to identify genomic associations with prostacyclin response. Of 129 patients identified, 54 met our criteria for “responders.” These patients were younger, more likely to be male, and were less likely to have connective tissue disease-related PAH. At follow-up, responders had improved hemodynamics, 6-min walk distance, and long-term survival. Baseline PA oxygen saturation (hazard ratio [HR] 0.568 [0.34–0.95]) and follow-up FC (HR = 2.57 [1.22–5.43]) were associated with survival. Prostacyclin responders were enriched in alleles related to cell development and circulatory system development and pathways related to aldosterone metabolism, cAMP signaling, and vascular smooth muscle contraction (P < 0.001). Age at treatment initiation, WHO FC at short-term follow-up, and PA O2% are associated with survival in patients with PAH exposed to parenteral prostacyclins. Exploratory genetic analysis yielded associations in biologically relevant pathways in the pathogenesis of PAH.
Pulmonary circulation | 2018
Bin Q. Yang; Tufik R. Assad; Jared O'Leary; Meng Xu; Stephen J. Halliday; Reid D'Amico; Eric Farber-Eger; Quinn S. Wells; Anna R. Hemnes; Evan L. Brittain
African Americans (AA) have a higher incidence of pulmonary hypertension (PH) risk factors. Few studies have examined the racial differences in the prevalence and etiology of PH and direct comparison of invasive hemodynamics between AAs and Caucasians has rarely been reported. In this study, we examined whether racial differences exist in patients referred for right heart catheterization (RHC) and hypothesized that AA race is an independent risk factor for PH and is associated with increased adjusted mortality. We extracted data for AA and Caucasian patients who underwent RHC at Vanderbilt between 1998 and 2014. Clinical information was obtained from Vanderbilts Synthetic Derivative, a de-identified mirror of our Electronic Medical Record. A total of 4576 patients were analyzed, including 586 (13%) AAs and 3990 (87%) Caucasians. AAs were younger than Caucasians by an average of eight years, but had more prevalent heart failure, features of metabolic syndrome, and higher creatinine. AAs also had higher mean pulmonary artery pressure and pulmonary vascular resistance. After adjusting for relevant co-morbidities, the AA race is associated with 41% increased risk of PH (odds ratio [OR] = 1.41, 95% confidence interval [CI] = 1.12–1.79). Among patients with PH, AA race is associated with 24% increased adjusted mortality (hazard ratio [HR] = 1.24, 95% CI = 1.09–1.45). AAs were younger but had more prevalent cardiometabolic and renal disease and worse pulmonary hemodynamics. The AA race is an independent risk factor for PH. Among patients with PH, the AA race is associated with increased adjusted mortality. Future studies should focus on delineating whether genetic or environmental factors contribute to PH risk in AAs.
Journal of Heart and Lung Transplantation | 2015
Stephen J. Halliday; Anna R. Hemnes; Ivan M. Robbins; Meredith E. Pugh; David Zhao; Robert N. Piana; Pete Fong; Evan L. Brittain
Journal of the American College of Cardiology | 2018
Robert Colbert; Shi Huang; Tufik R. Assad; Stephen J. Halliday; Reid D'Amico; James West; Evan L. Brittain
Journal of the American College of Cardiology | 2017
Bin Yang; Tufik R. Assad; Reid D'Amico; Stephen J. Halliday; Meng Xu; Eric Farber-Eger; Quinn S. Wells; Evan L. Brittain
Journal of Heart and Lung Transplantation | 2014
Evan L. Brittain; Stephen J. Halliday; Meredith E. Pugh; Anna R. Hemnes; Ivan M. Robbins